

ASX/MEDIA RELEASE

6th June 2017

Combined FOXFIRE Study Data Presented at ASCO Annual Meeting

Sydney, Australia; 6th June 2017 – Sirtex Medical Limited (ASX:SRX) announces the oral abstract of the combined SIRFLOX/FOXFIRE/FOXFIRE Global studies comparing SIR-Spheres[®] Y-90 resin microspheres plus standard of care systemic chemotherapy versus systemic chemotherapy alone in non-resectable, first-line metastatic colorectal cancer (mCRC) patients, was presented at the gastrointestinal (colorectal) cancer session at the American Society of Clinical Oncology (ASCO) Annual Meeting today¹.

Dr David N. Cade, Chief Medical Officer of Sirtex Medical said "The presentation of the combined FOXFIRE analysis by Professor Sharma at ASCO now confirms that while SIR-Spheres plus systemic chemotherapy did not meet the primary endpoint of an overall survival advantage over chemotherapy alone, a statistically significant benefit was observed in objective response rates and liver-specific progression. Also, the initial data presented from the SIRFLOX and FOXFIRE Global analyses, did confirm a statistically significant reduction in the risk of death for those patients who received SIR-Spheres plus chemotherapy with a right-sided primary colon cancer. Across both studies, the incidence of a right-sided primary colon cancer was 24%. We eagerly await further data presentation on all three studies and clinician feedback on this interesting finding at future medical conferences."

Professor Ricky Sharma, the Principal Investigator of the FOXFIRE study and Chair of Radiation Oncology at University College London said "Although overall survival is the gold standard for randomised phase III clinical trials, it is often difficult to see statistically significant results since patients have multiple lines of therapy after they receive the new treatment and there is no way of controlling cross-over to the new treatment after the patient has completed protocol therapy. Even in a very large phase III study, it is difficult to control for all biological factors since researchers are still discovering previously unknown factors that drive cancer, for example recent studies that show that right-sided colorectal cancer is a different disease from left-sided colorectal cancer whereas we classified them as a single disease when we planned the FOXFIRE and SIRFLOX studies over a decade ago."

Dr Andrew Kennedy, Physician in Chief, Radiation Oncology and Director, Radiation Oncology Research at the Sarah Cannon Research Institute commented "The results in first line patients reported in this abstract do not alter the established benefit of radioembolisation for patients beyond first line therapy. It is very encouraging that a potential benefit in survival for right-sided colon cancer patients receiving chemotherapy plus hepatic radiation is suggested by these data as it is already established that many patients derive benefit from liver-directed radiotherapy to treat metastases as proven with level I and II medical evidence of efficacy and safety."

The combined SIRFLOX/FOXFIRE/FOXFIRE Global study was the largest ever interventional oncology study with a liver-directed therapy, namely SIR-Spheres microspheres, to examine OS in the first-line mCRC setting with standard of care systemic chemotherapy with or without biologic therapy. A total of 1,103 patients were enrolled across all three studies.

Further data on the impact of primary tumour location on overall survival will be presented at the 19th European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer (WCGIC) in Barcelona, Spain from 28th June to 1st July. Unless embargoed by the scientific committee of the meeting, the abstract release date will be 4pm AEST on Wednesday 28th June.

Head Office

Level 33, 101 Miller Street North Sydney, NSW 2060 Australia Americas 300 Unicorn Park Drive Woburn, MA 01801 United States **Europe, Middle East & Africa** Josef-Schumpeter-Allee 33 53227 Bonn Germany Asia Pacific 50 Science Park Road, #01-01 The Kendall Science Park II Singapore 117406 Professor Sharma's ASCO presentation is attached.

- ENDS -

About SIRFLOX/FOXFIRE/FOXFIRE Global

The aim of the SIRFLOX/FOXFIRE/FOXFIRE Global studies is to prospectively combine clinical data from the three similarly designed individual trials to allow adequate power to evaluate the impact of chemotherapy with Selective Internal Radiation Therapy (SIRT) using SIR-Spheres[®] Y-90 resin microspheres on overall survival in first-line metastatic colorectal cancer, in over 1,100 patients. Efficacy and safety estimates derived using individual participant data (IPD) from SIRFLOX, FOXFIRE, and FOXFIRE Global will be pooled using 2-stage prospective meta-analysis. Secondary outcome measures include progression-free survival (PFS), liver-specific PFS, health-related quality of life, response rate, resection rate, and adverse event profile. The potential treatment benefit in those patients who present with disease confined to the liver will be also be investigated.

About Colorectal Cancer

Colorectal cancer (CRC or bowel cancer) occurs when cancerous cells develop in the patient's colon or rectum. CRC is the third most common form of cancer worldwide, making up about 10% of all cancers. In 2012, an estimated 1.4 million new cases were diagnosed globally and 694,000 cancer deaths were attributed to CRC.²

About SIR-Spheres[®] Y-90 Resin Microspheres

SIR-Spheres Y-90 resin microspheres are a medical device used in interventional oncology and delivered via Selective Internal Radiation Therapy (SIRT), also known as radioembolisation, directly to liver tumours. SIR-Spheres Y-90 resin microspheres are approved for supply in key markets, such as the United States, European Union and Australia.

About Sirtex Medical

Sirtex Medical Limited (ASX:SRX) is an Australian-based global healthcare business working to improve outcomes in people with cancer. Our current lead product is a targeted radiation therapy for liver cancer. Over 73,000 doses have been supplied to treat patients with liver cancer at 1,060 medical centres in over 40 countries. For more information please visit <u>www.sirtex.com</u>.

For further information, please contact:

Investor Enquiries:

Dr David N. Cade CMO Sirtex Medical Limited Phone: +61 (0) 2 9964 8400

Investor/Media Enquiries:

Dr Tom Duthy Global Investor Relations Manager Sirtex Medical Limited Phone: +61 (0) 2 9964 8427 Email: <u>tduthy@sirtex.com</u>

SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd

¹ Sharma RA et al. Overall survival analysis of the FOXFIRE prospective randomized studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer. *2017 ASCO Annual Meeting; J Clin Oncol* 2017; **35** (Suppl): Abs 3507.

² World Cancer Report, 2014; Geneva, WHO: 2014; 1.1.



Sirtex Medical Limited

SIRFLOX/FOXFIRE/FOXFIRE Global Combined Clinical Study ASCO Oral Abstract Presentation



6 June 2017



Overall survival analysis of the FOXFIRE prospective randomized studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer

Professor Ricky Sharma Chair of Radiation Oncology, University College London, United Kingdom

on behalf of the FOXFIRE, SIRFLOX and FOXFIRE-Global Investigators









Selective Internal Radiation Therapy (SIRT)

- SIRT involves injection of millions of yttrium-90 labelled resin microspheres directly in to the blood supply of primary or secondary liver tumors
 - A single large radiation dose
 - FDA approved in 2002 for unresectable liver tumors
 - Supported by NCCN Guidelines (Category 2A) and ESMO Guidelines (II,B)
 - Commissioned in several countries for mCRC patients refractory to chemotherapy

Hendlisz A et al. *J Clin Oncol* 28: 3687-3694, 2010. NCCN Guidelines: Rectal Cancer v1.2017. NCCN Guidelines: Colon Cancer v1.2017 Van Cutsem E et al. Ann Oncol 27: 1386-1422, 2016





Liver metastases from colorectal cancer

- >1 million diagnoses of CRC every year
- 40-50% of patients develop liver metastases
- · SIRT plus FOLFOX has an acceptable safety profile
- SIRT plus FOLFOX as first-line therapy improves local control of liver metastases

Sharma RA et al. J Clin Oncol 25: 1099-1106, 2007 Van Hazel G et al. J Clin Oncol 34: 1723-1731, 2016





Three prospective randomized studies planned for combined analysis of overall survival

| Study name | Geographic region | Recruitment completed | Patients recruited |
|----------------|----------------------|-----------------------|-----------------------|
| SIRFLOX | ANZ, EME, USA | 2013 | 530 |
| FOXFIRE | UK | 2014 | 364 |
| FOXFIRE Global | ANZ, AP, EME, USA | 2014 | 209 |
| | | Total recruitment | 1,103 |

Virdee PS et al. JMIR Res Protocol 28: e43, 2017






Key eligibility criteria

- Adenocarcinoma of the colon or rectum
- · Liver metastases not surgically resectable or ablatable
- Eligible for systemic chemotherapy as first-line treatment for metastatic CRC
- WHO Performance Status 0 1
- Limited extra-hepatic metastases
- Permitted to have primary tumor in situ
- · No evidence of ascites, cirrhosis, portal hypertension





Treatment schedule







Study endpoints

Primary endpoint

Overall survival (time from randomization to all-cause death)

Secondary endpoints

- PFS at any site (independent central imaging review)
- Liver-specific PFS (independent central imaging review)
- Objective tumor response rate at any site (RECIST v1.0)
- · Hepatic resection rate
- Toxicity & safety (NCI CTCAE v3.0)
- · Health-related quality of life





Statistics


- · Specified in protocol:
 - Hazard Ratio 0.8, 80% power, 2-sided 5% alpha
 - 710 OS events to detect increase in median OS from 19.7 months (control arm) to 24.6 months (experimental arm)
- Statistical methods (all Intention-to-Treat, except for safety):
 - OS and PFS analyzed by Cox regression and 2-stage meta-analysis using individual patient data (IPD)
 - Liver-specific PFS analyzed by Competing Risk regression and 1-stage meta-analysis to account for competing risks: First site of progression not involving the liver; death without radiological progression documented

Virdee PS et al. JMIR Res Protocol 28: e43, 2017 Fine J & Gray RJ. Am Stat Assoc 94: 496-508, 1999





Study flow chart







Patient characteristics

| Characteristic | Chemo (n = 549) | Chemo+SIRT (n = 554) |
|--|--------------------|-------------------------|
| Median age in years (range) | 63 (23 – 89) | 63 (28 – 90) |
| Male | 65.8% | 65.5% |
| WHO performance status 0 1 | 63.2% 36.4% | 63.9% 35.7% |
| Extra-hepatic metastases | 34.8% | 35.9% |
| >25% liver involvement | 30.6% | 32.3% |
| Intent to treat with biologicals | 54.5% | 53.8% |
| Synchronous presentation with liver mets | 86.5% | 87.2% |
| Primary tumor in situ | 55.0% | 50.2% |





Treatment characteristics

| Characteristic | Chemo (n = 549) | Chemo+SIRT (n = 554) |
|--|--------------------|---------------------------------------|
| Did not receive SIRT: Total Reasons in FOXFIRE: • Clinical deterioration • Aberrant vascular anatomy/lung shunting • Withdrew consent to SIRT | - - - | 8.5% (33.3%) (40.0%) (20.0%) |
| Cycles of oxaliplatin received at full protocol dose | 49.1% | 43.8% |
| Median (IQR) number of cycles of FOLFOX chemotherapy | 12 (7-13) | 12 (7-15) |
| Patients receiving bevacizumab | 46.6% | 35.6% |
| Patients receiving cetuximab | 1.6% | 0.7% |






Overall survival (n=1103) 1.00 Median Events n Chemo 549 23.3 months 411 Chemo+SIRT 554 433 22.6 months 0.75-Proportion Alive HR: 1.04 (95% CI: 0.90-1.19) p=0.609 0.50-0.25 0.00-Т 36 12 24 48 60 0 Time from Randomisation (months) No. at Risk Chemo 549 419 242 88 33 12 35 Chemo+SIRT 554 91 17 417 247





Overall survival by study








Treatment effect on OS within subgroups


| Subgroup | n | Events | HR (95% CI) |
|--------------------------------|----------|--------|--------------------|
| Liver-only | 713 | 525 | 1.00 (0.85 - 1.19) |
| Liver-dominant | 390 | 319 | 1.07 (0.85 - 1.33) |
| Liver involvement ≤ 25% | 754 | 545 | 1.00 (0.84 - 1.18) |
| Liver involvement > 25% | 347 | 297 | 1.12 (0.89 - 1.41) |
| Age < 65 years | 623 | 470 | 0.97 (0.81 - 1.16) |
| Age ≥ 65 years | 479 | 374 | 1.14 (0.93 - 1.41) |
| Male | 724 | 556 | 1.11 (0.94 - 1.31) |
| Female | 378 | 288 | 0.88 (0.70 - 1.12) |
| No primary tumor in situ | 521 | 390 | 0.98 (0.80 - 1.19) |
| Primary tumor in situ | 580 | 453 | 1.10 (0.92 - 1.33) |
| WHO performance status 0 | 701 | 514 | 1.03 (0.86 - 1.22) |
| WHO performance status 1 | 398 | 328 | 1.07 (0.86 - 1.32) |
| Primary tumor location - left | 540 | 389 | 1.14 (0.93 - 1.39) |
| Primary tumor location - right | 179 | 147 | 0.67 (0.48 - 0.92) |
| Bevacizumab received | 465 | 336 | 0.97 (0.78 - 1.20) |
| Bevacizumab not received | 638 | 508 | 1.04 (0.87 - 1.24) |
| Synchronous disease | 958 | 739 | 1.02 (0.89 - 1.18) |
| Metachronous disease | 139 | 101 | 0.99 (0.66 - 1.48) |








Progression-free survival








Progression-free survival by study








Liver-specific Progression-Free Survival








Waterfall plot of best radiological response








Best radiological response by study







Resection rate








Selected all-cause adverse events (safety population)

| Adverse events | Chemo (n = 571) | Chemo+SIRT (n = 507) |
|---|---|--------------------------------------|
| All patients any grade All patients grade ≥3 All patients grade 5 | 99.6% 66.5% 1.9% | 99.8% 74.0 % 2.0% |
| Hematological (grade ≥3) Neutropenia Febrile neutropenia Thrombocytopenia Leukopenia | 24.2% 2.8% 1.2% 2.3% | 36.7% 6.5% 7.7% 5.9% |
| Non-hematological (grade ≥3) Fatigue Abdominal pain Diarrhea Peripheral neuropathy Radiation hepatitis | 4.9% 2.3% 6.5% 5.8% | 8.5% 6.1% 6.7% 3.6% 0.8% |






Grade 3+ adverse events per cycle of chemotherapy








Post-protocol systemic treatment or SIRT







Health Related Quality of Life: EQ5D (US tariff)







Conclusions

- Addition of SIRT to FOLFOX first-line chemotherapy in patients with liveronly or liver-dominant mCRC did not improve OS or PFS
- Significant benefit in liver-specific PFS and radiological response rate was achieved by the addition of SIRT
- Toxicity was higher in FOLFOX+SIRT group, particularly hematological
- FOLFOX+SIRT patients were less likely to receive bevacizumab and to receive subsequent post-protocol systemic therapy
- Liver metastases from right-sided primary merit evaluation in other datasets as a subgroup who may derive additional clinical benefit from SIRT





Acknowledgements

- Trial participants and their families
- Investigators
- NCRI Colorectal Clinical Study Group
- NCRI CTRad Working Group
- UK NIHR Clinical Research Network and equivalent in devolved nations
- Oxford Clinical Trials Research Unit, University of Oxford









Thank you

